Vysis ALK Break Apart FISH Probe Kit detects rearrangements involving the ALK gene via fluorescence in situ hybridization (FISH) technology in non-small cell lung cancer (NSCLC) tissue specimens.
Reduce variability with ready-to-use components
Vysis ALK Break Apart FISH Probe Kit features:
Premixed, optimized probes
ALK positive control slides
ALK negative control slides
Ready-to-use slide preparation reagents
Manual and Automation Options
Approved for use on the BioView imaging system
NCCN™ Guidelines Version 2.2017 for Non-Small Cell Lung Cancer
Recommend ALK rearrangement testing concurrently with EGFR mutation testing for diagnosing the following NSCLC histological subtypes: adenocarcinomas, large cell carcinomas, and NOS (not otherwise specified)
Consider ALK rearrangement and EGFR mutation testing in patients with mixed squamous histology if: they are never smokers, small biopsy specimens were used for testing, or mixed histology was reported.
States that a molecular diagnostic test that uses fluorescence in situ hybridization (FISH) is approved by the FDA to determine which patients with NSCLC are positive for ALK rearrangements, and is a prerequisite before crizotinib therapy.